Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl (transdermal patch + oral transmucosal lozenge) is a combination of two pharmaceutical formulations of the potent synthetic opioid analgesic fentanyl. The transdermal patch delivers a continuous dose of fentanyl through the skin for up to 72 hours and is primarily used for managing severe chronic pain in opioid-tolerant patients. The oral transmucosal lozenge ("lollipop") provides rapid-onset pain relief by allowing absorption through the buccal mucosa and is typically indicated for breakthrough cancer pain in opioid-tolerant individuals. Fentanyl acts as a full agonist at the mu-opioid receptor, producing analgesia and euphoria but also carrying significant risks including respiratory depression and potential for abuse or overdose[1][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl (transdermal patch + oral transmucosal lozenge).